Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Milei Threatens Falkland Oil Firms With Sanctions 
Add as a preferred source on Google
SOLANA BEACH, Calif., Feb. 21, 2018 -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that the Company will release financial results for the fourth quarter and full year ended December 31, 2017 on Wednesday, March 7, 2018, after the market closes.
Evoke will hold a conference call on Wednesday, March 7, 2018 at 4:30 pm ET to discuss the results. Participants should dial 1-877-407-0789 (United States) or 1-201-689-8562 (International) and mention Evoke Pharma. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.evokepharma.com.
After the live webcast, the event will be archived on Evoke's website for one year. In addition, a telephonic replay of the call will be available until March 14, 2018. The replay can be accessed by dialing 1-844-512-2921 (United States) or 1-412-317-6671 (International) with confirmation code 13676791.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The Company is developing Gimoti, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms. Gimoti is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through nasal administration. Visit www.EvokePharma.com for more information.
Investor Contact:
The Ruth Group
Tram Bui
Tel: 646-536-7035
[email protected]
